tbuckley/cabot-search huggingface dataset:
P103 Apples and pears? a comparison of two sources of lung cancer data in england
Authors: A Khakwani, R Hubbard, R Jack, N Wood, S Vernon, P Beckett, N Navani, S Harden, R Dickinson, I Woolhouse
Journal: Thorax (2016)

<h3>Introduction</h3> In 2014, the contract to deliver the National Lung Cancer Audit (NLCA) was awarded to the Royal College of Physicians. Data were previously submitted using a bespoke dataset (LUCADA), but will now be submitted via the nationally mandated Cancer Outcome and Services Dataset (COSD) and linked to additional cancer registry datasets. For patients diagnosed in 2014, NLCA data were submitted using LUCADA for 132 of 151 English trusts. Trusts also submitted data via COSD and registry data were produced by the National Cancer Registration Analysis Service (NCRAS), providing the opportunity to compare both datasets for data completeness and reliability. <h3>Methods</h3> We have linked the LUCADA and cancer registration datasets at patient level and assessed completeness of key patient variables including age, sex, stage, performance status and pathological confirmation, as well as recording/dates of treatment received. We assessed the inter-rater/data agreement of these variables using Cohen’s kappa statistics (k). Finally, we carried out a qualitative assessment on a subset of cases to explore reasons why patients were represented in one dataset but not the other. <h3>Results</h3> There were 26,001 patients in both datasets (94% of LUCADA data) with more in the registry dataset and not LUCADA than vice versa. Recorded sex and age were highly congruent, as was trust first seen which was the same in 96%. 56% of the patients had the same date of diagnosis, 74% were ± 7 days and 86% were ± 14 days of each other. The cancer registry data had a larger proportion of patients with missing PS (27% vs 11%) with agreement on PS (where available) being 97% (k = 0.91). Agreement on stage was 94% (k = 0.81). Agreement for surgery, chemotherapy and radiotherapy was 0.86, 0.88 and 0.77 respectively. Details of the qualitative work and trust first seen algorithms will be provided in the presentation. <h3>Conclusion</h3> Results suggest that cancer registry data accurately describe key patient features. Compared with LUCADA, the national cancer registry: identified more patients has a higher proportion pathological confirmation identified more patients with surgery, chemotherapy and radiotherapy has a higher proportion of missing data for PS which could be due to data entry transition
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Authors: Deborah A. Thomas, Hagop M. Kantarjian, Jorge Cortes, Stefan Faderl, Francis Giles, Guillermo Garcia-Manero, William Wierda, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Srdan Verstovsek, Michael Andreeff, Laurie A. Letvak, Dan Jones, Richard Champlin, Susan O’Brien
Journal: Blood (2006)
Gene Expression Profiling of Paired Pre- and Post-Prednisolone (PRED) BM Samples from Childhood ALL Identifies Robust Signatures for PRED Response and Eventual Outcome.
Authors: Yi Lu, Huiqing Liu, Ying Xu, Pei Lin Koh, Ariffin Hany, Limsoon Wong, Allen Eng Juh Yeoh
Journal: Blood (2006)
Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.
Authors: B. Bruno, M. Ladetto, M. Astolfi, L. Veneziano, L. Cimolin, E. Galletto, G. Pagliano, M. Rotta, N. Mordini, L. Giaccone, P. Omedè, S. Battaglio, R. Storb, M. Boccadoro
Journal: Blood (2004)
Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients
Authors: Vit Prochazka, Tereza Dyskova, Zuzana Prouzova, Tomas Papajik, Jiri Minarik, Juraj Duras, Jozef Michalka, Alice Sykorova, Peter Mikula, Ludek Raida, Eva Kriegova
Journal: Blood (2015)
Palmitic Acid, As Verified Using Lipid Profiling By Secondary Ion Mass Spectrometry, Demonstrates Anti-Tumor Activity Against Multiple Myeloma
Authors: Yasuyuki Nagata, Itsuko Ishizaki, Michihiko Waki, Yoshimi Ide, Md Amir Hossen, Kazunori Ohnishi, Mitsutoshi Setou
Journal: Blood (2014)
Controlled Release: Photocleavable Hydrogels for Light-Triggered siRNA Release (Adv. Healthcare Mater. 3/2016)
Authors: Cong Truc Huynh, Minh Khanh Nguyen, Gulen Yesilbag Tonga, Lionel Longé, Vincent M. Rotello, Eben Alsberg
Journal: Advanced Healthcare Materials (2016)

“On-demand” release of genetic material for regulation of cell gene expression to control cell behavior is an innovative strategy for disease therapeutics and tissue regeneration. On page 305, E. Alsberg and co-workers explore a photolabile hydrogel system that can be used to actively tune the release of siRNA via the application of external UV light. The cover image illustrates how external UV light drives hydrogel degradation, and this accelerates the release of siRNA to ultimately alter gene expression of recipient cells.
Adenovirus Specific T-Cell Lines Devoid of Alloreactivity Against Haploidentical Recipients Can Be Obtained Using a Set of Adenovirus Hexon Peptides.
Authors: Patrizia Comoli, Marco W. Schilham, Sabrina Basso, Tamara van Vreeswijk, Rita Maccario, Maarten J.D. van Tol, Franco Locatelli, Louise A. Veltrop-Duits
Journal: Blood (2007)
AB0861 Prognostic Value of Ana Positivity in Greek Adult JIA Patients
Authors: D. Dimopoulou, M. Trachana, P. Pratsidou, P. Sidiropoulos, V. Tzimouli, F. Kanakoudi-Tsakalidou, A. Garyfallos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Antinuclear antibodies (ANA), one of the biomarkers of ILAR JIA classification, has been proposed to be associated with a protracted disease course overtime, regardless of JIA subtype. However, their role in the disease outcome is still debated. <h3>Objectives</h3> To investigate the impact of ANA positivity in the long-term outcome of JIA patients. <h3>Methods</h3> Patients ≥18 years with an established JIA, a minimal disease duration of 5 years and no history of a &gt;6–month care from external rheumatologists, were enrolled in the study. Data were retrieved from the patients9 charts, including ANA titers at onset (2 measurements, 3 months apart). The ANA were measured by indirect immunofluorescence (cut-off value ≥1:160). Clinical, laboratory -including ANA- and radiographic assessment were performed at the last follow-up visit, 17.2 years post-diagnosis. The outcome variables defined were: radiographic damage assessed by the total modified Sharp/van der Heijde Score (TmSvdHS), articular and extra-articular damage by Juvenile Arthritis Damage Index (JADI-A and JADI-E), physical ability by the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the cumulative % times spent in a state of disease activity and of clinical remission off medication (CR). <h3>Results</h3> Hundred two patients (72 females) were enrolled. The disease age of onset (mean ±SD) was 7.7±4 years, the interval from onset to last visit 17.2±6.7 years and the patients9 current age 25±5.9 years. Thirty three (32.4%) patients were ANA positive at onset. At the last follow-up, there was no significant difference between ANA positive and ANA negative patients in terms of TmSvdHS (p=0.982), JADI-A (p=0.699), JADI-E (p=0.235), HAQ-DI (p=0.234), cumulative % time spent in disease activity (p=0.583) or CR (p=0.175). There was no statistical gender difference among ANA positive patients (F:M 36.6%:25%, p=0.385), but they had an earlier disease onset (p=0.038), mostly oligoarticular (p=0.004) and were more prone to uveitis development (p=0.001). In the multivariate analysis ANA positivity was found to be the single independent risk factor for uveitis development [OR (95%) 10.703 (1.821, 62.899), p=0.009]. <h3>Conclusions</h3> Patients with ANA positive had predominantly an earlier and oligoarticular disease onset and a higher risk of uveitis development. However, ANA positivity was not found to influence the final disease outcome in terms of articular and extra articular degree of damage, radiographic abnormalities, physical disability and cumulative % time spent in disease activity or CR. <h3>References</h3> Martini et al.(2010). Ann Rheum Dis. 69:1260–3, Ravelli et al.(2011) Arthritis Rheum. 63:267–75. <h3>Disclosure of Interest</h3> None declared
DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.
Authors: Richard A. Van Etten, Wayne W. Chan, Virginia M. Zaleskas, Peter Evangelista, Katherine Lazarides, Cong Peng, Shaoguang Li, Scott C. Wise, Peter Petillo, Daniel L. Flynn
Journal: Blood (2007)
Protein-crystal interface mediates cell adhesion and proangiogenic secretion
Authors: Fei Wu, Weisi Chen, Brian Gillis, Claudia Fischbach, Lara A Estroff, Delphine Gourdon
Journal: Biomaterials (2016)

The nanoscale materials properties of bone apatite crystals have been implicated in breast cancer bone metastasis and their interactions with extracellular matrix proteins are likely involved. In this study, we used geologic hydroxyapatite (HAP, Ca
THU0402 Radiographic Progression Is Associated with Increased Cardiovascular Risk in Patients with Axial Spondyloarthritis
Authors: K.Y. Kang, S. Bahk
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A recent study showed that patients with chronic inflammatory arthritis have an increased risk of cardiovascular disease (CVD). Axial sponayloarthritis (axSpA) is also thought to carry an increased cardiovascular (CV) risk, but it is unclear whether axSpA patients have a higher risk of CVD than the general population. <h3>Objectives</h3> To compare the cardiovascular disease (CVD) risk between axial spondyloarthritis (axSpA) patients and matched controls, and to identify factors associated with increased CVD risk in axSpA patients. <h3>Methods</h3> This cross-sectional study enrolled 185 axSpA patients who fulfilled the ASAS criteria and 925 ageand sex-matched controls. None of the subjects had a previous history of CVD or diabetes mellitus. Traditional CVD risk factors were assessed and the 10 year CVD risk was calculated using the Framingham risk score (FRS). Estimated 10 year CVD risk was compared between axSpA patients and matched controls. Disease activity and radiographic progression in the sacroiliac joint and spine of axSpA patients were evaluated at the time of CVD risk assessment. <h3>Results</h3> HDL cholesterol levels were lower in axSpA patients than in matched controls (p=0.004); however, systolic blood pressure was higher (p&lt;0.001). The FRS was 5.0 ± 6.6% for controls and 6.3 ± 8.7% for axSpA patients (p=0.046). Both the grade of sacroiliitis on X-ray and the number of syndesmophytes correlated with the FRS (p=0.009 and p=0.001, respectively), but disease activity variables did not. The FRS was significantly higher in axSpA patients with a greater number of syndesmophytes (p=0.035). Multivariate analysis identified the grade of sacroiliitis and number of syndesmophytes as being independently associated with the FRS (p=0.003 and p=0.042, respectively). <h3>Conclusions</h3> The FRS was higher in axSpA patients than in a matched general population. Radiographic progression in the spine and sacroiliac joints was associated with a high estimated 10 year CVD risk. <h3>Disclosure of Interest</h3> None declared
FRI0207 Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Rheumatoid Arthritis Patients
Authors: J.R. Curtis, F. Xie, H. Yun, S. Bernatsky, K.L. Winthrop
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> While placebo-controlled clinical trials have suggested an increased rate of herpes zoster (shingles) with tofacitinib, the real-world risks of herpes zoster and herpes simplex associated with tofacitinib compared to other biologics for rheumatoid arthritis are largely unknown. <h3>Objectives</h3> To evaluate the risks of herpes zoster (HZ) and herpes simplex virus infection (HSV) associated with tofacitinib compared to biologic agents among patients with rheumatoid arthritis (RA). <h3>Methods</h3> Using health plan data, we identified RA patients without a history of HZ or HSV who initiated tofacitinib or biologics from 2010–2013. Among this cohort, new cases of HZ or HSV were found and incidence rates calculatedby drug. We used Cox proportional hazards models evaluated the adjusted association between tofacitinib and either HZ, and a composite outcome of HZ or HSV. <h3>Results</h3> A total of N=1,746 patients initiating tofacitinib were compared with initiations of other biologics including anti-TNF (n=38,871), abatacept (n=11,434), rituximab (n=4,785), and tocilizumab (n=6,266). Tofacitinib patients were somewhat younger (mean age 57 years) versus those on other biologics, and somewhat less likely to use concomitant MTX (39% vs. 44–56%, depending on drug). Crude incidence of HZ associated with tofacitinib was 4.33/100py and after multivariable adjustment, was significantly elevated (hazard ratio, HR=2.09, 95% CI 1.33–3.26) compared to abatacept (referent). Rates and adjusted HRs for all other RA biologics were comparable to each other and abatacept. Older age, female sex, prednisone &gt;7.5mg/day, prior outpatient infection, and greater number of hospitalizations were also associated with increased HZ risk Incidence rates for the combined outcome were greatest for tofacitinib (9.33/100py) and also significantly elevated after adjustment (HR=1.65, 95%CI 1.21–2.23). <h3>Conclusions</h3> Zoster infections were relatively common among RA patients. The risk for zoster associated with tofacitinib was approximately double that observed in patients using biologics. <h3>Acknowledgement</h3> This project had no external funding <h3>Disclosure of Interest</h3> J. Curtis Grant/research support from: Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, Consultant for: Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, F. Xie: None declared, H. Yun Grant/research support from: Amgen, S. Bernatsky Grant/research support from: Supported by the Drug Safety and Effectiveness Network, Canadian Institutes of Health Research, K. Winthrop Grant/research support from: Unrelated work with Pfizer, UCB, Genentech, AbbVie, Lilly, BMS, Consultant for: unrelated work with Pfizer, UCB, Genentech, AbbVie, Lilly, BMS
Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.
Authors: Roberto F Machado, Robyn J Barst, Nancy A Yovetich, Kathryn L Hassell, Jonathan C. Goldsmith, Rob Woolson, Victor R. Gordeuk, Simon Gibbs, Jane A Little, Gregory J Kato, Dean E Schraufnagel, Lakshmanan Krishnamurti, Reda E Girgis, Claudia R. Morris, Erika Berman-Rosenzweig, David B Badesch, Myron A Waclawiw, Mark Gladwin
Journal: Blood (2009)
THU0559 Frequency of fibromyalgia Syndrome in Patients with Type 2 Diabetes Mellitus
Authors: G. Tugrul, N. Cuzdan Coskun, T. Sarpel, M. Sert, E. Nazlican
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fibromyalgia Syndrome (FS) is a chronic condition with widespread pain. Increased FS prevalence was observed in patients with Diabetes Mellitus (DM) in several of former studies.<sup>1,2</sup> <h3>Objectives</h3> The aim of this study is to assess the frequency of FS in patients with Type 2 DM. Additionally; we aimed to evaluate the association of pain severity with disease control of DM. <h3>Methods</h3> Patients with Type 2 DM who were followed in Endocrinology Clinic of Cukurova University Hospital were included in the study. FS was diagnosed according to 2013 Alternative Criteria set by American College of Rheumatology. Patients with anemia, hyper- and hypothyroidism, malignancy, pregnancy and rheumatologic conditions were excluded. Patients9 pain during morning and sleep was evaluated by Visual Analog Scale (VAS). Fasting blood glucose and Hba1c levels were measured to assess disease control of DM. <h3>Results</h3> Ninety-two patients (61 female, 31 male) with Type 2 DM were included in the study. Mean age of the patients was 57.84 ± 10.01 years. FS was diagnosed in 4.3% of the patients. No significant difference was observed between Hba1c levels of Type 2 DM patients with and without FS (<i>P</i>=0.87). Mean VAS scores of the patients during morning and sleep were detected as 2.97±2.96 and 2.51±2.73 respectively. There was a weak negative correlation between VAS morning scores and Hba1c levels in diabetic patients (r=-0.24, <i>P</i>=0.04). There were no correlations of VAS sleep scores with fasting glucose and Hba1c levels (<i>P</i>=0.54, <i>P=</i>0.34 respectively). <h3>Conclusions</h3> According to the results of the present study, when diagnosis is based on 2013 alternative criteria of ACR, FS frequency in patients with Type 2 DM is found to be similar to that of among healthy populations. Yet, better control of blood glucose levels might decrease daily pain in diabetic patients. <h3>References</h3> Yanmaz MN, Mert M, Korkmaz M. The prevalence of fibromyalgia syndrome in a group of patients with diabetes mellitus. Rheumatol Int. 2012 Apr;32(4):871–4. Tishler M, Smorodin T, Vazina-Amit M, Ramot Y, Koffler M, Fishel B. Fibromyalgia in diabetes mellitus. Rheumatol Int. 2003 Jul;23(4):171–3 <h3>Disclosure of Interest</h3> None declared
Euthanasia or Assisted Suicide in Patients With Psychiatric Illness—Reply
Authors: Emilie Olié, Philippe Courtet
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.
Authors: David Dingli, Robert A. Kyle, Vincent S. Rajkumar, Grzegorz S. Nowakowski, Dirk R. Larson, John P. Bida, Morie A. Gertz, Angela Dispenzieri, L. J. Melton, Terry M. Therneau, Jerry A. Katzmann
Journal: Blood (2005)
Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)
Authors: Jeff P. Sharman, Leonard M. Klein, Michael Boxer, Kathryn S. Kolibaba, Steve Abella, Clarence Eng, Jing He, Jing Hu, Christopher A. Yasenchak
Journal: Blood (2015)
ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity
Authors: Bonnie K. Harrington, Michael Gulrajani, Todd Covey, Allard Kaptein, Bart Van Lith, Raquel Izumi, Ahmed Hamdy, Roger Glenn Ulrich, John C Byrd, Brian J Lannutti, Amy J. Johnson
Journal: Blood (2015)
FRI0308 Surface Tetherin Is A Novel Cell-Specific Biomarker for Interferon Response in Systemic Lupus Erythematosus
Authors: Y. El-Sherbiny, M.Y. Md Yusof, E. Hensor, M. Wittmann, P. Emery, E. Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Type I interferons (IFN-I) have diverse effects on immune cell populations in SLE, Measuring IFN-I response using PBMCs or whole blood interferon-stimulated gene (ISG) expression does not completely explain clinical features of SLE and IFN blocking therapy. Furthermore, the proportions of cell populations in blood altered with disease activity. Bone marrow stromal antigen 2/Tetherin (BST2), is a cell surface protein eminent in viral immunology as interferon-induced viral restricting molecule expressed on most circulating leucocytes. <h3>Objectives</h3> To develop a cell-specific IFN-I assay <h3>Methods</h3> PBMCs were collected from 133 SLE patients and 19 healthy controls. Disease activity was measured using BILAG-2004. PBMCs were analysed by flow cytometry for cell surface BST2 protein on each immune cell subset. Cells were FACS-sorted into naïve and memory B-cells, plasmablasts, CD3+ T-cells, NK-cells and monocytes in 12 SLE patients and 16 healthy controls. Expression of <i>BST2,</i> as well as 32 other ISGs, were measured using qPCR and a 33-gene IFN score calculated. <h3>Results</h3> Analysis of sorted cells confirmed that surface BST2 is a valid cell-specific IFN assay. <i>BST2</i> expression correlated with BST2 surface protein within each immune subset: naïve B-cells (r=0.63, p=0.009); memory B-cells (r=0.78, p&lt;0.001); plasmablasts (r=0.58, p=0.018); NK cells (0.63, p=0.008); T-cells (r=0.61, p=0.012); monocytes (r=0.47, p=0.064). We next used surface BST2 to compare IFN activity of each subset with clinical features in 133 patients. A strong correlation between the PBMC 33-gene IFN score and surface BST2 was found for each cell subset (all p&lt;0.001) confirming validity of BST2 as a biomarker. BST2 was significantly higher in SLE than HC on naïve and memory B-cells (p=0.004, p=0.003), plasmablasts (p=0.047), T cells (p=0.043), but not different on monocytes (p=0.406). Association of total BILAG score with BST2 on naïve and memory B-cells (Tau-a =0.23 and 0.22 respectively) was substantive and approximately twice as strong as monocytes and T-cells (Tau-a =0.12 and 0.14). A similar pattern was seen for anti-dsDNA titre, with no association with monocyte BST-2 (Tau-a =0.07) but a substantive association for memory B cell BST-2 (Tau-a =0.18). <h3>Conclusions</h3> IFN-I response differs in cell subsets. This can be measured in a fast, cost-effective, convenient assay using flow cytometric analysis of surface BST2. Our results show that IFN activity measured on B cells is more clinically relevant than on other cell populations. <h3>Disclosure of Interest</h3> None declared
Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.
Authors: Dennis J. Kuo, Norman J. Lacayo, Don Hoang, Dejan Juric, Susana C. Raimondi, David Chen, Myron N. Chang, Yaddanapudi Ravindranath, Howard J. Weinstein, Branimir I. Sikic, Gary Van Houten Dahl
Journal: Blood (2005)